In vitro testing of blood contacting materials before clinical application is generally advisable. Four heparin coatings from different manufacturers were tested for adsorbed proteins and soluble activation markers. The surface with the highest antithrombin, thrombin, high-molecular-weight-kininogen (HMWK) and the lowest fibrinogen binding capacity (Carmeda, Medtronic) showed significantly lower levels of granulocytes and platelet activation (β-TG, PMN-elastase release). No statistically significant differences in soluble markers of the coagulation system could be detected (F1+2, TAT). Interestingly, complement activation (TCC) was significantly reduced within the group of the lowest adsorption of the complement factor C3.
Our data demonstrate that there is a relation between the binding affinity of proteins (C1-inhibitor, C3-complement) and the consecutive changes in complement activation (TCC). Therefore, measuring adsorbed proteins on artificial surfaces is a suitable, sensitive and very reproducible method for assessing the thrombogenicity of biomaterials.
1. Salzman, E., Merril, E., Kent, K.Interaction of blood with artificial surfaces. In: Bloom, A.L., Forbes, C.D., Thomas, D.P., Tuddenham, E.G.D. (edtrs): Haemostasis and Thrombosis, Churchill Livingstone, Edinburgh (1994).
2.
2. Wendel, H.P., Ziemer, G."Coating-techniques to improve the hemocompatibility of artificial surfaces used for extracorporeal circulation,"Eur J Cardiothorac Surg, 16, 1-9 (1999).
3.
3. Horbett, T.A."Principles underlying the role of adsorbed plasma proteins in blood interactions with foreign materials."Cardiovasc Pathol, 137-148 (1993).
5. Larm, O., Larsson, R., Olsson, P."A new non-thrombogenic surface prepared by selective covalent binding of heparin via a modified reducing terminal residue,"Biomater Med Devices Artif Organs, 11, 161-173 (1983).
6.
6. Heyman, P.W., Cho, C.S., McRea, J.C., Olsen, D.B., Kim, S.W."Heparinized polyurethanes: in vitro and in vivo studies,"J Biomed Mater Res, 19, 419-436 (1985).
7.
7. Pasche, B., Kodama, K., Larm, O., Olsson, P., Swedenborg, J."Thrombin inactivation on surfaces with covalently bonded heparin,"Thromb Res, 44, 739-748 (1986).
8.
8. Toomasian, J.M., Hsu, L.C., Hirschl, R.B., Heiss, K.F., Hultquist, K.A., Bartlett, R.H."Evaluation of Duraflo II heparin coating in prolonged extracorporeal membrane oxygenation,"ASAIO Trans, 34, 410-414 (1988).
9.
9. Von Segesser, L.K., Turina, M."Cardiopulmonary bypass without systemic heparinization. Performance of heparin-coated oxygenators in comparison with classic membrane and bubble oxygenators,"J Thorac Cardiovasc Surg, 98, 386-396 (1989).
10.
10. Palatianos, G.M., Dewanjee, K.M., Kapadvanjwala, M., Novak St, Sfakianakis, G.N., Kaiser, G.A."Cardiopulmonary Bypass with a Surface-Heparinized Extracorporeal Perfusion system,"ASAIO Trans, 36, M476-M479 (1990).
11.
11. Tong, S.D., Rolfs, M.R., Hsu, L.C."Evaluation of Duraflo II heparin immobilized cardiopulmonary bypass circuits,"ASAIO Trans, 36, M654-M656 (1990).
12.
12. Videm, V., Svennevig, J.L., Fosse, E., Semb, G., Osterud, A., Mollnes, T.E., Nielsen, H."Reduced complement activation with heparin-coated oxygenator and tubings in coronary bypass operations,"J Thorac Cardiovasc Surg, 103, 806-813 (1992).
13.
13. Gu, Y.J., van Oeveren, W., Akkerman, C., Boonstra, P.W., Huyzen, R.J., Wildevuur, C.R.H."Heparin-coated circuits reduce the inflammatory response to cardiopulmonary bypass,"Ann Thorac Surg, 55, 917-922 (1993).
14.
14. Sanchez, J., Elgue, G., Riesenfeld, J., Olsson, P."Control of contact activation on end-point immobilized heparin: the role of antithrombin and the specific antithrombin-binding sequence,"J Biomed Mater Res, 29, 655-661 (1995).
15.
15. Choay, J., Petitou, M., Lormeau, J.C., Sinay, P., Casu, B., Gatti, G."Structure-activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity,"Biochem Biophys Res Commun, 116, 492-499 (1983).
16.
16. Lane, D.A., Denton, J., Flynn, A.M., Thunberg, L., Lindahl, U."Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4,"Biochem J, 218, 725-732 (1984).
17.
17. Danielsson, A., Raub, E., Lindahl, U., Bjork, I."Role of ternary complexes, in which heparin binds both antithrombin and proteinase, in the acceleration of the reactions between antithrombin and thrombin or factor Xa,"J Biol Chem, 261, 15467-15473 (1986).
18.
18. Bradford, M.M."A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding,"Anal Biochem, 72, 248-254 (1976).
19.
19. Lindhout, T., Blezer, R., Schoen, P., Willems, G.M., Fouache, B., Verhoeven, M., Hendriks, M., Cahalan, L., Cahalan, P.T."Antithrombin activity of surface-bound heparin studied under flow conditions,"J Biomed Mater Res, 29, 1255-1266 (1995).
20.
20. Vroman, L."The life of an artificial device in contact with blood: initial events and their effect on its final state,"Bull NY Acad Med, 64, 352-357 (1988).
21.
21. Santerre, J.P., ten Hove, P., Brash, J.L."Polyurethanes bearing pendant amino acids: Fibrinogen adsorption and coagulant properties,"J Biomed Mater Res, 26, 1003-1018 (1992).
22.
22. Andrade, J.D., Hlady, V., Wei, A.P., Lea, A.S., Jeon, S.I., Lin, Y.S., Stroup, E."Proteins at interfaces: Principles, multivariate aspects, protein resistant surfaces, and direct imaging and manipulation of adsorbed proteins,"Clin Mater,11, 67-84 (1992).
23.
23. Cornelius, R.M., Brash, J.L."Identification of proteins adsorbed to hemodialyser membranes from heparinized plasma,"J Biomater Sci Polym Ed, 4, 291-304 (1993).
24.
24. Slack, S.M., Horbett, T.A."Changes in fibrinogen adsorbed to segmented polyurethanes and hydroxyethylmethacrylate copolymers,"J Biomed Mater Res, 26, 1633-1649 (1992).
25.
25. Mulzer, S.R., Brash, J.L."Analysis of proteins adsorbed to glass from human plasma using immunoblotting methods,"J Biomater Sci Polym Ed, 1, 173-182 (1990).
26.
26. Brash, J.L., ten Hove P."Transient adsorption of fibrinogen on foreign surfaces: Similar behavior in plasma and whole blood,"J Biomed Mater Res, 23, 157-169 (1989).
27.
27. Mulzer, S.R., Brash, J.L."Identification of plasma proteins adsorbed to hemodialyzers during clinical use,"J Biomed Mater Res, 23, 1483-1504 (1989).
28.
28. Elwing, H., Askendal, A., Lundström, I."Competition between adsorbed fibrinogen and high-molecular-weight kininogen on solid surfaces incubated in human plasma (the Vroman effect): Influence of solid surface wettability,"J Biomed Mater Res, 21, 1023-1028 (1987).
29.
29. Vroman, L., Adams, A.L."Rapid identification of proteins on flat surfaces, using antibody-coated metal oxide suspensions,"J Immunol Methods, 93, 213-216 (1986).
30.
30. Vroman, L., Adams, A.L., Fischer, G.C., Munoz, P.C."Interaction of high molecular weight kininogen, factor XII, and fibrinogen in plasma at interfaces,"Blood, 55, 156-159 (1980).
31.
31. Bale, M.D., Wohlfahrt, L.A., Mosher, D.F., Tomasini, B., Sutton, R.C."Identification of vitronectin as a major plasma protein adsorbed on polymer surfaces of different copolymer composition,"Blood, 74, 2698-2706 (1989).
32.
32. Vroman, L."Methods of investigating protein interactions on artificial and natural surfaces,"Ann N Y Acad Sci, 516, 300-305 (1987).
33.
33. Hammer, D.A., Apte, S.M."Simulation of cell rolling and adhesion on surfaces in shear flow: general results and analysis of selectin-mediated neutrophil adhesion,"Biophys J, 63, 35-57 (1992).
34.
34. Finn, A., Rebuck, N., Moat, N."Neutrophil activation during cardiopulmonary bypass,"J Cardiovasc Surg, 104, 1746-1748 (1992).
35.
35. Butler, J., Pillai, R., Rocker, G.M., Westaby, S., Parker, D., Shale, D.J."Effect of cardiopulmonary bypass on systemic release of neutrophil elastase and tumor necrosis factor,"J Cardiovasc Surg, 105, 25-30 (1993).
36.
36. Stahl, R.F., Fisher, C.A., Kucich, U., Weinbaum, G., Warsaw, D.S., Stenach, N., O'Connor, C., Addonizio, V.P."Effects of simulated extracorporeal circulation on human leucocyte elastase release, superoxide generation, and procoagulant activity,"J Thorac Cardiovasc Surg, 101, 230-239 (1991).
37.
37. Rothe, G., Kellermann, W., Valet, G."Flow cytometric parameters of neutrophil function as early indicators of sepsis- or trauma-related pulmonary or cardiovascular organ failure,"J Lab Clin Med, 115, 52-61 (1990).
39. Lundblad, R., Moen, O., Fosse, E."Endothelin-1 and neutrophil activation during heparin-coated cardiopulmonary bypass,"Ann Thorac Surg, 63, 1361-1367 (1997).
40.
40. Wan, S., LeClerc, J.L., Vincent, J.L."Inflammatory response to cardiopulmonary bypass: mechanisms involved and possible therapeutic strategies,"Chest, 112, 676-692 (1997).
41.
41. Didisheim, D., and Watson, J.Thromboembolic complications of cardiovascular devices and artificial surfaces. In: Kwaan, H., and Samama, M.Y. (edtrs): Clinical thrombosis, CRC, Boca Raton (1989).
42.
42. Mammen, E.F."Contact activation: The interaction of clotting, fibrinolytic, kinin and complement systems,"Biomedical Progress, 2, 31-34 (1990).
43.
43. Moen, O., Hogasen, K., Fosse, E., Dregelid, E., Brockmeier, V., Venge, P., Harboe, M., Mollnes, T.E."Attenuation of changes in leukocyte surface markers and complement activation with heparin-coated cardiopulmonary bypass,"Ann Thorac Surg, 63, 105-111 (1997).
44.
44. Jansen, P.G., te Velthuis, H., Huybregts, R.A., Paulus, R., Bulder, E.R., van der Spoel, H.I., Bezemer, P.D., Slaats, E.H., Eijsman, L., Wildevuur, C.R.H."Reduced complement activation and improved postoperative performance after cardiopulmonary bypass with heparin-coated circuits,"J Thorac Cardiovasc Surg, 110, 829-834 (1995).
